Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Medivir, Audiocast with teleconference, Q2'24

By Inderes8/22/2024, 12:00 PM
Medivir

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Unknown 1
00:00 - 02:13

Thank you very much and warm welcome, everyone, to the quarter two results webcast here at Medivir. I hope everyone has had a great summer as we sort of kick off again after a warm and long summer vacation. And here at Medivir, we closed out quarter two sort of at the beginning of the summer on a very high note when we presented strong data set for the Fostrox and Lenvima combination at the ESMO Congress in Munich. And we will come back to that and share a bit more details today in terms of the data presented and how we're now working forward with the Fostrox development program. So important information which you will find as you access the presentation on the website. And as mentioned in quarter two, we were able to share a very exciting data set at ESMO GI where we could see, for the Fostrox and Lenvima combination, a superior efficacy compared with what has been shown in previous published studies in the second line liver cancer space. And equally important, we could confirm in that data set. And Fredrik will come back to that in a bit more detail. The liver targeted approach, i.e., the killing of cancer cells in the liver without having a negative impact on normal liver function, highly important for the treatment of liver cancer. And, in addition, we are also accelerating the Fostrox development according to plan. And in the room with me, I have, of course, our CFO, Magnus Christensen, who will sort of come back to the financial details at the end. And I'm also in the room with CMO Pia Baumann, who will go through the clinical data from ESMO GI and that will be accompanied by our CSO.

Unknown 2
02:14 - 02:14

Right.

Unknown 1
02:19 - 04:48

So as mentioned, the full focus here at mid-year is the continued acceleration of Fostrox's development. We've shared data previously, but that data set was highly strengthened by the median time to progression that we showed at ESMO GI of 10.8 months. And before we go into details, just to take a slightly step back, one of the things that we are seeing in liver cancer is not the most common type of tumor today, but it is a tumor type that is growing quite rapidly. It's the fastest growing tumor type in the US, driven largely by the obesity pandemic we are seeing, which is contributing to a strong increase in fatty liver disease, which also contributes quite strongly to patients or people being diagnosed with, advanced liver cancer. And as we have shared previously, we are now in the middle of running our global phase 1B-2A study, which we are running across three different countries and 15 sites. And we are closing in on the end of the study, we shared an updated data set at ESMO, and we very much look forward to sharing additional details of the study and a more mature data set at the ESMO conference in Barcelona in a couple of weeks, or actually 3 or 4 weeks. And before I then hand over to Pia to go through the clinical data that we presented a couple of months back. Today is an exciting day. It's an important day. Today marks the two-year anniversary of the longest treated patient in the study. And it's a patient that is still on treatment and is still responding to treatment. So highly, highly encouraging from an ability to stay on treatment long term and most importantly, to benefit long term from treatment. So with that, I hand over to Pia to go through more of the details in terms of what we shared a few months back.

Pia Baumann
04:50 - 06:13

So at the latest presentation at ESMO GI. We had data from the outset from the phase 1B-2A study with Fostrox plus Lenvima. And it was in 21 patients who had progressed mainly on immunotherapy combinations. As you can see here, just to remind you a little bit about all the patients in this study and what these characteristics do they have. That means that 70% of these patients had primarily been treated locally with TACE, but also with other local therapies. And about 70% had metastases also outside the liver. And this is important for the combination as it is really liver targeted. But we are combining it with what we think is the best available second-line treatment. And to ensure treatment also reaches the metastases outside the liver. So, I will actually hand over to Friedrich to go through a couple of details that were presented in this poster at ESMO GI, focusing on the tumor selectivity and the data from the biopsies that were conducted. So, Fredrik, please go ahead.

Fredrik Öberg
06:14 - 10:24

Thank you. So, as you all know, one of the key objectives when developing cancer therapy is selectivity. You really want to kill tumor cells without negatively affecting normal cells in the body. We have incorporated several features in the molecule for Fostrox that achieve this. You will remember that we built this molecule on the experience of delivering drugs to the liver. Inhibiting hepatitis C virus. The product contains features that give the molecule liver-directed activity, so it is stable in the GI tract, stable in blood, but rapidly metabolized in the liver. Uh, so that's one aspect. High exposure in the liver. Uh, low systemic exposure. That would harm the patient. And this we have demonstrated in preclinical models that we can achieve a really significant increase in liver exposure over normal delivery of chemotherapy. Another feature to mention is that these patients, as we will discuss, have poor liver function. Uh, and we really do not want to affect the liver negatively. So other features of the molecule are that the orange part here is designed to inhibit DNA replication but not other aspects of cellular function, thereby sparing normal hepatocytes. So, the features we designed into the molecule. And if we move to the next slide, we're really happy to see that this pans out in the clinical study. Patients in cycle two of the combination study with Lenvima had biopsies, and these biopsies were analyzed. Um, and in this panel on the left, you will see both pre-dose archival tissue biopsies and biopsies on treatment. What I can draw your attention to is the increase in DNA damage. So that's a feature that we normally don't see in the tumor unless the patients are treated. And it signifies DNA damage induced by Fostrox. Additionally, we observe hypoxia indicated by increased expression of the glucose transporter. And this is a feature of Lenvima IIb. Lenvima inhibits angiogenesis and induces hypoxia in the tumor. Hypoxia can actually synergize with the mechanism of action of Fostrox. On the right-hand panel is the summary of the data regarding DNA damage from the agent. Valuable biopsies that we took. We can see that there's a significant increase in DNA damage in tumor tissue. However, gratifyingly. We do not see DNA damage in the adjacent liver tissue, suggesting that we have a selective tumor effect, not only a selective liver-directed effect. So with that, I leave it to Pia to continue with the clinical data.

Pia Baumann
10:24 - 17:36

Thank you. And, I mean, it's really important, what you talked about, this synergistic action with Lenvatinib as well. And that becomes even more important that Fostrox is selective in the liver because otherwise, you might also enhance the toxicity in the liver. And as Fredrik already said, we have a patient population with poor liver function. Tumor selectivity is paramount when treating liver tumors. So, we don't want to impair liver function further. So, to confirm the results from the biopsy that Fredrik just talked about, we could see that what you see here on the slide is longitudinal liver enzyme data, ALT, and AST. It's to the left. And also supporting the fact that we didn't have any sort of negative effect in combination with platinum. Something else that you often look at when examining liver cancer patients is the ALBI score. And that is assessed to evaluate liver function. It's albumin plus bilirubin. This analysis that we have from our data shows that the ALBI score, as you can see to the right here, was stable with no change in the score. And that further supports the selectivity and also the tolerability, which is a prerequisite for efficacy. And in order to stay on the treatment to have a longer-term benefit, I think we should move to the next slide. In our earlier presentation, we showcased encouraging efficacy data. I'm sure that you have seen this already, with an overall response rate of 24% and a disease control rate of 81% in this population. Again, it is a poor prognosis. Population. And at ESMO GI, the estimated median time to progression was 10.8 months, which is very long in this patient population. At that time, five patients were still remaining on this trial. At this point in the study, the data has matured enough to allow us to use the standard Kaplan-Meier approach with the median time to progression (TTP). And this is an estimate of what the median time to progression is most likely to be at the time of the final read of the study. So this is what we normally use. We have presented before, like an actual time point, which is not the standard way of doing it, but that has been due to the fact that the data has not been mature enough. We can go to the next slide. So, to put this median time to progression (TTP) of 10.8 months, seen in this phase 1B2A study into context, we are comparing it with Lenvima and other second-line treatments in HCC. And when we do that, it becomes clear that 10.8 months is quite a bit longer than the around four months in median TTP or PFS seen in studies that we have listed here to the right. This is not a comprehensive list, but as you remember, we have talked about before, this is like a stone or a data desert where we don't have much data. So with the Lenvima data in second-line after immunotherapy, it's mainly retrospective data and what we can see that this is the first part of the list is that we have TTP or PFS around 2 to 6 months, and this is really similar to what is seen with other TKIs in the second-line HCC. And at the bottom of this list, uh, this is the data that was recently presented at ESMO. And it showed a disappointing PFS of only 2.8 months. What was used here was an immunotherapy combination in this case, pembrolizumab and regorafenib, in the second line after using an immunotherapy combination in the first line setting. And this really supports the need for switching to another mechanism of action than what was actually used in the first line study. So next slide. So, Jens has already talked a little bit about this, but we are excited. We are going to present data again. And the impact of the data from Medivir was discussed with Dr. Sean at ESMO. And that interview is available on the Medivir website. I have not looked at it yet, it is available on the Medivir website. ESMO GI in Barcelona is really around the corner, and we will present data on the 16th of September from this phase 1B2A study with Fostrox. And then we will present mature safety data because the primary endpoint was safety. And again, this is a prerequisite for efficacy. And we also now have mature efficacy results. Uh, this data will then later during the same day be shared and discussed in a webcast with Dr. Sean and myself. And, we will provide more information shortly. We can go to the next slide. So what is the next step here? Based on the encouraging data that you have seen from the phase 1B2A, we are continuing the planning and preparation for the randomized phase 2B study with Fostrox in combination with Lenvima versus Lenvima alone. And this is in second-line advanced HCC that have all received prior immunotherapy combination in the first line. The first part of this study, as you can see here on the slide, will be a dose optimization run-in. And the second part will continue with the selected dose. Also, randomization as you can see here. And the recruitment in this trial will take place in Europe, Asia, and in the US. And with our selection here. The feasibility study is currently ongoing. And with that, I will leave it to you.

Unknown 1
17:36 - 22:25

Yes, just to pick up on where I left off. I mean, this is a picture you have seen previously. That we have updated it along the way, just to highlight that we continue to move forward. Not sure if that's the best expression, but let's proceed with preparing for the next phase and continue the activities we agreed upon. The update here focuses on what can be noted in the green boxes, indicating that the study feasibility is well underway and progressing nicely. Uh, and similarly, with regards to working with the steering committee, selecting a PI and finalizing the protocols in order to open an IND in the US, and to apply for national approvals in different countries, everything is progressing very nicely. And as we've said before, we want to share the dataset as it matures and continues to improve regularly. And as we communicated earlier, we have acceptance to present at ESMO, which we are super happy about, because clearly that is the biggest and the most important oncology congress in Europe. So it's a good place to be with regards to generating attention for a good data set within a patient population where there is an urgent need for additional and effective treatment alternatives. So again, we continue to move ahead with a good pace with regards to preparing for the next phase. So, with that, just a kind of repetition, as we talked about before, just to remind everyone of that setup. Whereas, liver cancer, or the specific type of liver cancer as a disease, can sometimes be considered a relatively small market. But the secondhand market in and of itself is actually valued at over two and a half billion dollars by 2030. And most importantly, it continues to grow. And the growth numbers are probably, if anything, underestimated on the back of a very significant increase in sort of NASH-driven, fatty liver disease-driven liver cancer, seen not just in Western countries, but also Eastern countries. Most importantly, from a commercial opportunity perspective, it is essential to keep in mind that there are no approved treatment options in the second line setting today, after the IO combination. Almost all of the current studies ongoing are exploring and evaluating treatment alternatives in the first-line setting. So the competition in the second line is scarce. Most studies in the second-line setting use and switch to another IO. And as you remember a few minutes ago, Pia commented on the ASCO data set for Keytruda plus Regorafenib, where they evaluated switching to another IO in second line, which showed the same as has been observed in other tumor types. Switching to another I/O after the first line, I/O is rarely easy and encouraging. Encouraging clinical results. So with that, before I hand over to Magnus, in summary, we have shown today and it's great to see that sort of progress in the clinic as well. That's essentially the design of the drug manifesting in practical clinical terms as well. We have a unique and targeted mechanism that selectively kills cancer cells in the liver, which contributes to a strengthening of the data set and a super-strong benefit of 10.8 months until tumor progression in the second-line setting. In a market where we have a clear opportunity to be first, the market is worth over $2.5 billion on an annual basis. So with that, I hand over to Magnus. Thank you.

Magnus Christensen
22:26 - 22:33

Go to slide 20, please. We can see the financial summary for both the second quarter and the year to date.

Unknown 1
22:33 - 22:33

June.

Magnus Christensen
22:34 - 24:02

I will briefly comment on the Q2 results. All numbers are expressed in millions of dollars in sales. To start off, from a financial viewpoint, Q2 was in line with our plan, with no real surprises, which is always good. The total sums up to around 1 million. It relates to royalty income and other external expenditures, which are higher compared to last year in the quarter, and pertain to the cost of the ongoing combination study, as well as CMC costs for the next phase of Fostrox. Personnel costs are slightly higher and primarily relate to the share savings program that was implemented in the quarter. The operating loss for Q2 is -47, higher than last year in the quarter, and relates to the clinical and CMC costs mentioned earlier. The cash flow from operating activities in Q2 amounts to approximately 26 million minus, which is aligned with our plan for the year and the cash position at the end of Q2 is around 127. According to our current assumptions and plan, the cash run rate is projected into the end of Q1 2025. With this, I will hand back over to you.

Unknown 1
24:03 - 24:34

And now a brief summary again before we go to the Q&A session. We have a unique and targeted mechanism. We're showing a duration of benefit that hasn't been seen before in a very difficult-to-treat patient population with the opportunity to be first to market in a significantly high-value market that the second-line HCC space provides. With that, we conclude our presentation and move to the Q&A session.

Operator
24:39 - 24:59

To ask a question, please dial Pound Key five on your telephone keypad to enter the queue. To withdraw your question, please dial Pound Key six. The next question comes from Richard Romanus from Redeye. Please go ahead.

Unknown 3
25:04 - 25:39

Hello. Good afternoon. So I was thinking we could start where we left off. Regarding the funding situation, I was wondering, given that you have around 130 million left and guide that this will last until the end of Q1, what are the cost activities that you need to undertake in the next three quarters since this implies that costs will increase compared to Q2 and Q1?

Magnus Christensen
25:41 - 26:34

Hi, Richard, thank you for your question, which I really understand. If you calculate the money we have, taking into account the cash flow from operating activities in Q2, but to give a straightforward answer, the costs are not evenly distributed throughout the months and quarters. As mentioned, we have some CMC investments that we are currently making for the phase 2B, but of course, we follow this very closely and will provide updates if there are any changes. We examine each quarter and will keep everyone updated as necessary. But I can say that we will have a positive cash flow in Q1. Um, based on our current assumptions today. I hope that answers your question, Richard.

Unknown 3
26:34 - 26:40

Okay, I interpret that as meaning this is a conservative estimate.

Magnus Christensen
26:41 - 26:45

It's more conservative than having a positive viewpoint. Yes.

Unknown 3
26:47 - 27:18

Okay, and then a question for ESMO about the most critical thing you need to do now, which is finding a partner. So, could you tell me more about that process, and how it's going? What more data do you think a partner wants to see? Do you have all the data that's needed or any other preparations?

Unknown 1
27:19 - 29:39

I mean, I would say the following. I mean, it's partner discussions. And the question regarding the maturity of data will always be a fluid process. Of course, I mean, there will never be a sort of a set point in time when, okay, now it's not a binary sort of switch on and off. But I guess clearly from our perspective, we have seen throughout the year, from when we started at ESMO GI, that the data has strengthened. Patients have stayed on treatment longer. That has to some extent delayed the maturity of the study and the closing of the study. But the positive aspect is that the data has strengthened. In any partner discussions, you of course want to utilize as mature and strong data as you possibly can. But I think what we're alluding to now, and I think we commented on, kind of mentioned in the, in the, um, in the quarter two results, sort of in my introduction that we are looking forward to presenting more detailed and mature data, sort of from a safety perspective, definitely, but also from a clinical efficacy perspective at ESMO in Barcelona. So, we are reaching a point where the data we see from both an efficacy and safety perspective is nearing what could be considered a final outcome, though it's not the final readout. And that means that there's not much more from a data perspective with regards to partnering discussions. Moving to a situation where we have what we need, it's now time to close out any partnering discussions. I mean, we have had and continue to have discussions, but with regards to specific details, I think we've said all along that we will share information when we have news to share, when we have something to confirm.

Unknown 3
29:41 - 30:06

Yeah, that makes sense. I guess that's one reason you raised money earlier this year, to wait for data to mature. Yeah. Timeline question: When do you think you will be ready to submit the MDA? And when do you think phase two can start?

Unknown 1
30:07 - 31:14

I think we've conserved Conservatively. I'll recall the fact that you used the word 'conservative' before. What we have said is that we are looking to file for the IND in the second half of the year. That is a conservative estimate, in the sense that it is not going to come until the latter part of the year. But I think the important part is that the process, together with feasibility and other aspects, is progressing according to plan. And we've been, I think I've said this previously, frantically moving towards that. Would it be possible to initiate the study this year, given that I've concluded before that it's going to be a challenge? We plan to initiate the study at the beginning of the first half of 2025 from an IND perspective, without giving away a specific date. It's progressing well. Together with other preparatory activities.

Unknown 3
31:16 - 31:52

Okay, another thing came to my mind. That would be interesting to hear your thoughts on; perhaps I've asked this question before, but it's worth repeating. Repeating in a case. The patient characteristics in this positive plus environment study. The search represents a typical liver cancer patient in either a better or worse condition.

Pia Baumann
31:53 - 32:53

So, there are a couple of exclusion criteria. It depends on which trial you are looking at. Again, in this patient population, the trials are scarce. So now I'm talking mainly about the first-line population. Where you exclude patients, for example, who have. Now I'm going to go into a little bit of detail; they have a narrow macrovascular invasion in the vena cava, for example. We haven't excluded these patients because this is an all-comer population. We also have a talk coming up about second line. We always say that in the second line. Right. But we also have third-line patients. We didn't have strict exclusion criteria in our study, which means that we have more like an all-comers population. But they are very much aligned with what second-line patients would look like. If you're not in a clinical trial, that's what I mean. Like in the clinical settings.

Unknown 2
32:54 - 32:55

Yeah.

Unknown 3
32:55 - 32:59

Okay. Great. Great. Thank you.

Operator
33:05 - 33:27

As a reminder, if you wish to ask a question, please dial the pound key followed by five on your telephone keypad. There are no more questions at this time, so I will hand the conference back to the speakers for any closing comments.

Unknown 1
33:28 - 35:00

What I will do then is move the slide forward. And I'll repeat what I've said previously to end on that note. From a mechanistic point of view, we have a unique drug on our hands designed to treat liver cancer. It is treating liver cancer quite effectively, in a way we have seen in the second-line space before, and the combination is quite tolerable and very encouraging as we continue to prepare for the next phase. We're moving forward with as much speed as we possibly can, because there is a window of opportunity to be the first approved treatment alternative in a patient population where there is an extremely high unmet medical need, a population that is growing quite fast. Encouraged by the end of Q2, we now shift gears towards the next couple of weeks. We look forward to sharing additional updates and conducting a webcast with more details regarding study data, together with one of our key investigators from the ESMO Congress in Barcelona on September 16th. So, thank you everyone for dialing in and have a good rest of the day.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…